Results of the EV-103 Study in Patients With Advanced Urothelial Carcinoma

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder cancer.

The ANZUP 1301 trial showed that BCG and mitomycin showed similar DFS to BCG alone in NMIBC, but with 40% fewer BCG doses and similar safety.

A phase 1b trial plans to evaluate AKY-1189 for the treatment of Nectin-4–expressing tumors.

The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk NMIBC.

Disitamab vedotin plus toripalimab showed significant survival benefits vs chemo in first-line HER2+ advanced urothelial carcinoma, with a manageable safety profile.

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the POTOMAC trial.